Log in

CVE:KDAKDA Group Stock Price, Forecast & News

0.00 (0.00 %)
(As of 07/2/2020 06:11 AM ET)
Today's Range
Now: C$0.13
50-Day Range
MA: C$0.16
52-Week Range
Now: C$0.13
Volume1,000 shs
Average Volume65,964 shs
Market CapitalizationC$15.39 million
P/E RatioN/A
Dividend YieldN/A
KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Medical Distribution



Sales & Book Value

Annual SalesC$24.28 million
Cash FlowC$0.02 per share
Book ValueC($0.02) per share



Market CapC$15.39 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KDA and its competitors with MarketBeat's FREE daily newsletter.

KDA Group (CVE:KDA) Frequently Asked Questions

How has KDA Group's stock been impacted by COVID-19 (Coronavirus)?

KDA Group's stock was trading at C$0.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KDA stock has decreased by 7.1% and is now trading at C$0.13. View which stocks have been most impacted by Coronavirus.

Has KDA Group been receiving favorable news coverage?

Media headlines about KDA stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. KDA Group earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about KDA Group.

Who are some of KDA Group's key competitors?

Who are KDA Group's key executives?

KDA Group's management team includes the following people:
  • Mr. Marc Lemieux, Co-Founder, Chairman, Pres & CEO
  • Ms. Isabelle Bégin, Co-Founder, COO, Exec. VP of Pharmacy Services Division & Director
  • Mr. Michael Winslow Kinley, Interim CFO & Director (Age 68)

What is KDA Group's stock symbol?

KDA Group trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KDA."

How do I buy shares of KDA Group?

Shares of KDA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is KDA Group's stock price today?

One share of KDA stock can currently be purchased for approximately C$0.13.

How big of a company is KDA Group?

KDA Group has a market capitalization of C$15.39 million and generates C$24.28 million in revenue each year.

What is KDA Group's official website?

The official website for KDA Group is www.alliancepharma.ca.

How can I contact KDA Group?

The company can be reached via phone at 418-755-0821.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.